Sarepta (NAS: SRPT) made a 19% leap higher on Monday after the company's drug eteplirsen, which treats Duchenne muscular dystrophy, received more praise during a conference in London. In this video segment, Motley Fool health care analyst Brenton Flynn talks about what the company's focus will be from here forward, and how its potential competition in this space also helped the stock yesterday.
Sarepta is a company making huge moves at the moment, and it may continue to be a win for investors. But, while you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Conference Commentary Boosts Sarepta originally appeared on Fool.com.
Brenton Flynn owns shares of Sarepta Therapeutics. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.